Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
BioVaxys Technology ( (TSE:BIOV) ) has shared an update.
BioVaxys Technology Corp. announced the revocation of a management cease trade order by the British Columbia Securities Commission following the completion of its required financial filings. Additionally, the company has settled a debt of $60,000 by issuing 1,200,000 common shares, which are subject to a four-month statutory hold period. This development marks a positive step in BioVaxys’s operational transparency and financial management, potentially enhancing its credibility and stability in the biopharmaceutical industry.
More about BioVaxys Technology
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company based in British Columbia, Canada. It specializes in developing novel immunotherapies using its DPX™ immune-educating technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform. The company focuses on treating cancers, infectious diseases, antigen desensitization, and other immunological fields. Its clinical pipeline includes maveropepimut-S in Phase II for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum-resistant ovarian cancer, and BVX-0918, a personalized vaccine for late-stage ovarian cancer soon entering Phase I in Spain.
YTD Price Performance: -34.00%
Average Trading Volume: 261,133
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.3M
Learn more about BIOV stock on TipRanks’ Stock Analysis page.